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Fluconazole in vitro susceptibility test results for 140,767 yeasts were collected from 127 participating
investigators in 39 countries from June 1997 through December 2003. Data were collected on 79,343 yeast
isolates tested with voriconazole from 2001 through 2003. All investigators tested clinical yeast isolates by the
CLSI (formerly NCCLS) M44-A disk diffusion method. Test plates were automatically read and results were
recorded with the BIOMIC Vision Image Analysis System. Species, drug, zone diameter, susceptibility cate-
gory, and quality control results were collected quarterly via e-mail for analysis. Duplicate (the same patient,
same species, and same susceptible-resistant biotype profile during any 7-day period) and uncontrolled test
results were not analyzed. The 10 most common species of yeasts all showed less resistance to voriconazole than
to fluconazole. Candida krusei showed the largest difference, with over 70% resistance to fluconazole and less
than 8% to voriconazole. All species of yeasts tested were more susceptible to voriconazole than to fluconazole,
assuming proposed interpretive breakpoints of >17 mm (susceptible) and <13 mm (resistant) for voricon-
azole. MICs reported in this study were determined from the zone diameter in millimeters from the continuous
agar gradient around each disk, which was calibrated with MICs determined from the standard CLSI M27-A2
broth dilution method by balanced-weight regression analysis. The results from this investigation demonstrate
the broad spectrum of the azoles for most of the opportunistic yeast pathogens but also highlight several areas
where resistance may be progressing and/or where previously rare species may be “emerging.”
Antifungal resistance surveillance with a focus on Candida is
now widespread (5, 10, 17, 20, 29, 32). Most of these surveil-
lance efforts are by necessity limited in terms of the numbers of
participating sentinel sites and isolates tested. Furthermore,
none of the programs is extensive enough to provide temporal
and geographic data concerning the occurrence and resistance
profiles of the less common Candida species and other, non-
candidal opportunistic yeasts (21).
The ARTEMIS Global Antifungal Surveillance Program is
among the most comprehensive and long-running fungal
surveillance programs (6, 12, 17, 19, 22, 24, 25, 27). The
ARTEMIS Program is made up of two components: (i) a
broad international network of participating sites (127 sites in
39 countries), each of which performs Clinical and Laboratory
Standards Institute (CLSI, formerly National Committee for
Clinical and Laboratory Standards [NCCLS])-recommended
disk diffusion testing (M44-A) (14) of fluconazole and voricon-
azole against consecutive yeast isolates from a variety of clin-
ical sources (ARTEMIS DISK Surveillance Study) (6), and (ii)
a central reference laboratory (University of Iowa, Iowa City),
where CLSI-recommended broth microdilution (BMD) MIC
and disk diffusion testing (M27-A2 and M44-A, respectively)
(13, 14) is performed on blood and normally sterile-site iso-
lates of Candida and other opportunistic yeasts and molds
that are referred according to protocol from the participating
ARTEMIS study sites (19, 22, 24, 25, 27). As such, the
ARTEMIS Program has been designed to address many of the
potential limitations of resistance surveillance studies (7): (i) it
is both longitudinal (1997 to present) and global (127 partici-
pating sites in 39 countries) in scope, (ii) it employs standard-
ized antifungal susceptibility test methods (CLSI disk [M44-A]
and BMD MIC [M27-A2]) (13, 14), (iii) both internal quality
control (QC) performed in each participating laboratory and
external quality assurance measures are used to validate test
results (25, 27), (iv) results are recorded electronically using
the BIOMIC image analysis plate reader system (Giles Scien-
tific, Santa Barbara, Calif.) (6, 19, 25, 27) and are stored in a
central database, and (v) both Candida and non-Candida yeast
isolates obtained from consecutive clinical samples from all
body sites are tested locally, thus avoiding misleading results
based on biased selective testing. This so-called “routine” test-
ing is augmented by testing of isolates from blood and normally
sterile sites in the central reference laboratory (25, 27). Thus,
the ARTEMIS Program generates massive amounts of data
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that have been externally validated and that can be used to
identify temporal and geographic trends in the species distri-
bution of Candida and other opportunistic yeasts, as well as the
resistance profiles of these organisms to fluconazole and vori-
conazole as determined by standardized CLSI disk diffusion
testing.
In the present study, we utilized the results from the
ARTEMIS DISK Surveillance Program to evaluate global
trends in the susceptibility of yeasts to fluconazole over a
6.5-year period (140,767 isolates from 127 study sites in 39
countries; June 1997 through December 2003). We also report
results of voriconazole susceptibility testing performed on
79,343 isolates collected from 2001 to 2003. The scope of this
study provides an unprecedented look at the occurrence and
azole susceptibilities of several rare species of Candida, as well
as several of the other opportunistic yeasts. The study is limited
in that the numbers of isolates from certain regions are small
and the time frame over which voriconazole data are available
is relatively short.
MATERIALS AND METHODS
Organisms and test sites. A total of 134,715 isolates of Candida spp. and 6,052
isolates of noncandidal yeasts obtained from 127 different medical centers in
Asia (23 sites), Latin America (16 sites), Europe (74 sites), the Middle East (2
sites), and North America (12 sites) were collected and tested against fluconazole
between June 1997 and December 2003. In addition, a total of 79,343 isolates
(75,810 isolates of Candida spp. and 3,533 other yeasts) from 115 study sites in
35 countries were tested against voriconazole between 2001 and 2003. All yeasts
considered pathogens from all body sites (e.g., blood, normally sterile body
fluids, deep tissue, genital tract, gastrointestinal tract, respiratory tract, skin, and
soft tissue) and isolates from patients in all in-hospital locations during the study
period were tested. Yeasts considered by the local site investigator to be colo-
nizers, that is, not associated with an obvious pathology, were excluded, as were
duplicate isolates from a given patient (the same species and the same suscep-
tible-resistant biotype profile within any 7-day period). Identification of isolates
was performed in accordance with each site’s routine methods.
Susceptibility test method. Disk diffusion testing of fluconazole and voricon-
azole was performed as described by Hazen et al. (6) and in CLSI document
M44-A (14). Agar plates (150-mm diameter) containing Mueller-Hinton agar
(obtained locally at all sites) supplemented with 2% glucose and 0.5 g of
methylene blue per ml (MH-MB) at a depth of 4.0 mm were used. The agar
surface was inoculated by using a swab dipped in a cell suspension adjusted to the
turbidity of a 0.5 McFarland standard. Fluconazole (25-g) and voriconazole
(1-g) disks (Becton Dickinson, Sparks, Md.) were placed onto the surfaces of
the plates, and the plates were incubated in air at 35 to 37°C and read at 18 to
24 h. Slowly growing isolates, primarily members of the genus Cryptococcus, were
read after 48 h of incubation. Zone diameter endpoints were read at 80% growth
inhibition by using the BIOMIC image analysis plate reader system (version 5.9;
Giles Scientific, Santa Barbara, Calif.) (6, 19).
The interpretive criteria for the fluconazole and voriconazole disk diffusion
tests were those of the CLSI (1a, 14): susceptible (S), zone diameters of19 mm
(fluconazole) and 17 mm (voriconazole); susceptible dose dependent (SDD),
zone diameters of 15 to 18 mm (fluconazole) and 14 to 16 mm (voriconazole);
and resistant (R), zone diameters of 14 mm (fluconazole) and 13 mm (vori-
conazole). The corresponding MIC breakpoints (13) are as follows: S, MIC of8
g/ml (fluconazole) and 1 g/ml (voriconazole); SDD, MIC of 16 to 32 g/ml
(fluconazole) and 2 g/ml (voriconazole); R, MIC of 64 g/ml (fluconazole)
and 4 g/ml (voriconazole).
QC. QC was performed in accordance with CLSI document M44-A (14) by
using Candida albicans ATCC 90029 and C. parapsilosis ATCC 22019. A total of
5,865 and 5,484 QC results were obtained for fluconazole and voriconazole,
respectively, of which more than 99% were within the acceptable limits.
Analysis of results. All yeast disk test results were read by electronic image
analysis and interpreted and recorded with a BIOMIC Plate Reader System
(Giles Scientific Inc.). Test results were sent by e-mail to Giles Scientific for
analysis. The zone diameter, susceptibility category (S, SDD, or R), and QC test
results were all recorded electronically. In addition, MICs were calculated for
each drug-organism pair by the BIOMIC System software. The MIC-versus-zone-
diameter regression data used by the BIOMIC software were generated previ-
ously by ARTEMIS investigators (M.A.P. and M.G.R.) using CLSI BMD MIC
and disk test methods (19, 25, 27). Patient and doctor names, duplicate test
results (the same patient, the same species, and the same biotype results), and
uncontrolled results were automatically eliminated by the BIOMIC system prior
to analysis.
RESULTS
Isolation rates by species. A total of 140,767 yeast isolates
were collected and tested at 127 study sites between June 1997
and December 2003 (Table 1). Candida species accounted for
95 to 97% of all isolates in each study year (overall, 95.7%).
More than 16 different species of Candida were isolated, of
which Candida albicans was the most common (overall, 66.2%
of all Candida spp.). A decreasing trend in the rate of C.
albicans isolation (overall decrease, 10 to 11%) was noted over
the 6.5-year period. In contrast, increased rates of isolation of
C. tropicalis (an increase of 2.9% from 1997 to 2003) and C.
parapsilosis (an increase of 3.1% from 1997 to 2003) were
noted. Neither C. glabrata nor C. krusei showed a consistent
increase or decrease in isolation rate. Although isolates of
more unusual Candida species, such as C. guilliermondii, C.
kefyr, C. rugosa, and C. famata, constituted only a small per-
centage of the Candida isolates, the isolation rates of these
four species increased from 2- to 10-fold over the course of the
study. Likewise, although C. inconspicua, C. norvegensis, C.
lipolytica, C. pelliculosa, and C. zeylanoides are rare species of
Candida, the sheer size of the ARTEMIS database provides a
significant number of each of these species for study.
Among the noncandidal yeasts, Cryptococcus neoformans
(21% of 6,052 isolates), Saccharomyces spp. (6.8%), Trichos-
poron spp. (6.5%), and Rhodotorula spp. (2.3%) were the most
commonly identified species (Table 1). Unidentified (“other”)
yeasts represented 0.46 to 3.05% of all isolates. As noted pre-
viously (6), this percentage decreased somewhat over the
course of the study as more isolates were identified to the
species level.
Fluconazole and voriconazole susceptibilities of Candida
spp. Table 2 summarizes the in vitro susceptibilities of 78,463
and 75,787 isolates of Candida spp. to fluconazole and vori-
conazole, respectively, as determined by CLSI disk diffusion
testing. These isolates were obtained from 115 institutions in
35 countries during the period 2001 through 2003. The distri-
bution of zone diameters and their respective interpretive cat-
egories are shown in Fig. 1 for both agents. The percentages of
isolates in each category (S, SDD, and R) were 89.6%, 4.0%,
and 6.4% and 94.6%, 2.3%, and 3.1% for fluconazole and
voriconazole, respectively. Fluconazole was most active against
C. albicans (97.8% S), C. parapsilosis (93.2% S), C. lusitaniae
(93.3% S), C. kefyr (95.3% S), C. dubliniensis (96.8% S), and C.
pelliculosa (94.7% S). Decreased susceptibility to fluconazole
was seen with C. glabrata (66.7% S; 16.6% R), C. krusei (9.4%
S; 77.2% R), C. guilliermondii (73.3% S; 9.8% R), C. rugosa
(39.3% S; 51.8% R), C. famata (79.8% S; 11.9% R), C. incon-
spicua (25.7% S; 49.2% R), C. norvegensis (50.0% S; 38.0% R),
C. lipolytica (54.7% S; 39.6% R), and C. zeylanoides (54.1% S;
37.8% R). These findings confirm previously reported data for
the more common species (e.g., C. albicans, C. glabrata, C.
parapsilosis, and C. krusei) and markedly expand our under-
standing of the susceptibility, or lack thereof, of less common
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species, such as C. rugosa, C. inconspicua, and C. norvegensis, to
fluconazole (5, 15, 16, 18, 21, 23).
Voriconazole was significantly more active than fluconazole
against virtually every species, with the exception of C. tropi-
calis (89.1% S to fluconazole versus 87.1% S to voriconazole)
(Table 2). Among the species with decreased susceptibility to
fluconazole, more than 80% were susceptible to voriconazole,
including C. glabrata (81.7% S), C. krusei (83.2% S), C. guilli-
ermondii (91.2% S), C. famata (89.5% S), C. inconspicua
(89.2% S), and C. norvegensis (92.3% S). Among the flucon-
azole-resistant (zone diameter, 14 mm) isolates of C. gla-
brata, 30% remained susceptible (zone diameter, 17 mm)
to voriconazole; however, all voriconazole-resistant strains
were also resistant to fluconazole (reference 22 and data not
shown). Although voriconazole was more active than flucon-
azole against C. rugosa (61.4% S versus 39.3% S, respectively),
C. lipolytica (67.3% S versus 54.7% S, respectively), and C.
zeylanoides (74.3% S versus 54.1% S, respectively), these spe-
cies were markedly less susceptible and more resistant (11.4%
to 26.4%) to voriconazole than all other species of Candida.
Again, these data confirm and extend previous observations,
especially with the less common species of Candida (18, 20, 23,
24). Importantly, it is readily apparent from these data that
although some degree of cross-resistance may be seen between
fluconazole and voriconazole, it varies by species and should
not be assumed in the absence of species identification and
susceptibility testing results.
TABLE 1. Species distribution of Candida and other yeast isolates by year: ARTEMIS DISK Surveillance Program, 1997 to 2003a
Organism
1997–1998 1999 2000 2001 2002 2003
n % n % n % n % n % n %
Candida 22,533 95.2 20,998 95.7 11,698 97.0 21,804 96.3 24,680 95.3 33,002 95.5
C. albicans 16,514 69.77 14,667 66.87 7,961 66.02 14,268 62.99 15,147 58.51 20,576 59.56
C. glabrata 2,475 10.46 2,047 9.33 1,112 9.22 2,431 10.73 2,635 10.18 3,974 11.50
C. tropicalis 1,036 4.38 1,117 5.09 843 6.99 1,634 7.21 1,838 7.10 2,487 7.20
C. parapsilosis 955 4.03 1,028 4.68 650 5.39 1,501 6.63 1,632 6.30 2,406 6.96
C. krusei 372 1.57 459 2.09 376 3.12 544 2.40 639 2.47 884 2.56
C. guilliermondii 111 0.47 168 0.77 88 0.73 163 0.72 239 0.92 260 0.75
C. lusitaniae 115 0.49 99 0.45 62 0.51 122 0.54 131 0.51 211 0.61
C. kefyr 34 0.14 84 0.38 64 0.53 86 0.38 87 0.34 171 0.49
C. rugosa 7 0.03 7 0.03 21 0.17 151 0.67 150 0.58 116 0.34
C. famata 19 0.08 51 0.23 53 0.44 54 0.24 110 0.42 89 0.26
C. inconspicua 9 0.07 30 0.13 44 0.17 113 0.33
C. norvegensis 1 0.0 1 0.0 9 0.07 32 0.14 18 0.07 42 0.12
C. dubliniensis 1 0.01 19 0.08 26 0.10 18 0.05
C. lipolytica 7 0.06 14 0.06 14 0.05 25 0.07
C. zeylanoides 4 0.03 19 0.08 5 0.02 13 0.04
C. pelliculosa 1 0.01 14 0.06 12 0.05 12 0.03
Candida spp. 894 3.78 1,260 5.74 437 3.62 722 3.19 1,953 7.54 1,605 4.65
Other yeasts 1,131 4.8 950 4.3 361 3.0 849 3.7 1,210 4.7 1,547 4.5
Cryptococcus neoformans 275 1.16 334 1.52 79 0.66 312 1.38 575 2.22 463 1.34
Trichosporon spp. 68 0.29 77 0.35 107 0.89 134 0.59 118 0.46 139 0.40
Saccharomyces spp. 36 0.15 130 0.59 81 0.67 101 0.44 141 0.54 200 0.58
Rhodotorula spp. 33 0.14 31 0.14 17 0.14 17 0.08 42 0.16 80 0.23
Blastoschizomyces capitatus 1 0.01 17 0.08 22 0.08 16 0.05
Cryptococcus spp. 3 0.02 17 0.08 12 0.05 43 0.12
Pichia spp. 7 0.06 5 0.02 7 0.03 15 0.04
Hansenula anomala 10 0.08 2 0.01 9 0.03 2 0.01
Other yeast 723 3.05 378 1.72 56 0.46 244 1.08 284 1.10 589 1.70
Total 23,668 21,948 12,059 22,653 25,890 34,549
a Includes all specimen types and all locations in hospitals from a total of 121 different institutions.
TABLE 2. In vitro susceptibilities of Candida spp. to fluconazole
and voriconazole as determined by CLSI disk diffusion testing:
ARTEMIS DISK Surveillance Program, 2001 to 2003a
Species
Susceptibility
Fluconazoleb Voriconazoleb
n %S %R n %S %R
C. albicans 49,991 97.8 1.3 47,584 98.6 1.0
C. glabrata 9,040 66.7 16.6 8,719 81.7 10.1
C. tropicalis 5,959 89.1 5.0 5,643 87.1 6.7
C. parapsilosis 5,539 93.2 3.6 5,233 96.8 1.8
C. krusei 2,067 9.4 77.2 1,996 83.2 7.5
C. guilliermondii 662 73.3 9.8 633 91.2 4.9
C. lusitaniae 464 93.3 4.1 445 96.4 2.0
C. rugosa 417 39.3 51.8 394 61.4 26.4
C. kefyr 344 95.3 3.5 331 99.1 0.6
C. famata 253 79.8 11.9 238 89.5 5.5
C. inconspicua 187 25.7 49.2 186 89.2 5.4
C. norvegensis 92 50.0 38.0 91 92.3 1.1
C. dubliniensis 63 96.8 3.2 63 100.0 0.0
C. lipolytica 53 54.7 39.6 52 67.3 19.2
C. pelliculosa 38 94.7 0.0 38 100.00 0.0
C. zeylanoides 37 54.1 37.8 35 74.3 11.4
C. sake 12 83.3 8.3 12 100.0 0.0
Candida spp.c 4,245 86.6 8.2 4,094 92.7 4.7
a Isolates obtained from 115 institutions in 35 countries.
b Fluconazole and voriconazole disk diffusion testing was performed in accor-
dance with CLSI M44-A. Interpretive breakpoints: S, fluconazole 19 mm,
voriconazole 17 mm: R, fluconazole 14 mm, voriconazole 13 mm.
c Candida species not otherwise identified.
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Trends in resistance to fluconazole among Candida spp. over
a 6.5-year period. The longitudinal nature of the ARTEMIS
DISK Surveillance Program allows one to examine trends in
fluconazole resistance among clinical isolates of Candida spp.
with the important advantage of sufficient numbers of isolates
of each species, all tested by a single standardized method
(Table 3). Among the 10 species listed in Table 3, no consistent
increase or decrease in fluconazole resistance was seen over
time with C. albicans (range, 0.8% to 1.5%) or C. glabrata
(range, 14.3% to 22.8%). Although resistance among C. tropi-
calis isolates appeared to decline from 1997-1998 (4.2%) thru
2001 (3.0%), increases were seen in 2002 (6.6%) and 2003
(5.0%). A slight increase in resistance was noted over time
among C. parapsilosis and C. kefyr, whereas a major increase in
resistance was detected among isolates of C. rugosa, where 61.2
to 66.0% resistance was observed in the last 2 years of data
collection. In contrast, following a peak of 26.1% R in 2000,
resistance among isolates of C. guilliermondii decreased
steadily between 2001 (11.7% R) and 2003 (8.1% R). Although
C. famata appeared to be quite resistant to fluconazole in 1997
and 1998 (47.4% of 19 isolates), this was likely due to the small
number of isolates tested. As the numbers of C. famata isolates
increased to 50 per year over the next 5 years, the level of
resistance stabilized at 10 to 12%. Despite the increase in the
overall percentage of isolates of C. krusei that tested as resis-
tant to fluconazole, this is not an important finding, as the
species must be considered to be clinically resistant to flucon-
azole. The CLSI recommends that C. krusei not be tested
against fluconazole (13, 14). All such isolates should be re-
ported as fluconazole resistant.
Trends in resistance to voriconazole among Candida spp.,
2001 to 2003. Voriconazole has been used clinically since 2001
and since that time has been tested against Candida in the
ARTEMIS Global Surveillance Program (Table 4). Overall,
there has been a slight increase in the percentage of Candida
isolates that appear to be resistant (zone diameter, 13 mm)
to voriconazole, from 2.6% in 2001 to 3.5% in 2003. This may
be accounted for by increases in resistance observed with C.
glabrata (9.8% to 11.0%), C. tropicalis (4.7% to 7.0%), C.
rugosa (3.1 to 38.0%), C. lipolytica (7.7% to 12.0%), and un-
FIG. 1. Fluconazole (left) and voriconazole (right) zone diameter (in mm) distribution for all Candida spp.: 79,485 isolates tested against
fluconazole and 75,809 isolates tested against voriconazole. The isolates were obtained from 115 institutions in 34 countries from 2001 through
2003. Interpretive breakpoints: S, 19 mm (fluconazole) and 17 mm (voriconazole); SDD, 15 to 18 mm (fluconazole) and 14 to 16 mm
(voriconazole); R, 14 mm (fluconazole) and 13 mm (voriconazole).
TABLE 3. Trends in in vitro resistance to fluconazole among Candida spp. as determined by CLSI disk diffusion testing over
a 6.5-year period: ARTEMIS DISK Surveillance Program, 1997 to 2003a
Species
Resistanceb
1997–1998 1999 2000 2001 2002 2003
n %R n %R n %R n %R n %R n %R
C. albicans 16,514 0.8 14,677 0.8 7,961 1.5 14,268 1.0 15,147 1.5 20,576 1.4
C. glabrata 2,475 18.5 2,047 22.8 1,112 14.3 2,431 18.3 2,635 14.7 3,974 16.9
C. tropicalis 1,036 4.2 1,117 3.5 843 3.1 1,634 3.0 1,838 6.6 2,487 5.0
C. parapsilosis 955 2.0 1,028 2.8 650 2.9 1,501 4.2 1,632 3.9 2,406 3.0
C. krusei 372 56.5 459 71.5 376 68.1 544 70.4 639 78.9 884 80.2
C. guilliermondii 111 6.3 168 9.5 88 26.1 163 11.7 239 10.5 260 8.1
C. lusitaniae 115 2.6 99 4.0 62 1.6 122 6.6 131 4.6 211 2.4
C. kefyr 34 0.0 84 4.8 64 3.1 86 2.3 87 5.7 171 2.9
C. rugosa 7 28.6 7 14.3 21 42.9 151 30.5 150 66.0 116 61.2
C. famata 19 47.4 51 9.8 53 13.2 54 14.8 110 10.9 89 11.2
Candida spp.c 894 15.5 1,260 7.1 437 10.1 722 9.6 1,953 52 1,605 11.4
a Isolates from all specimen types and all hospital locations in 127 institutions.
b Zone 14 mm. Fluconazole disk diffusion testing performed in accordance with CLSI M44-A.
c Candida species not otherwise identified.
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identified Candida species (4.2% to 7.0%). In contrast, no
change or a decrease in resistance was seen with C. albicans, C.
parapsilosis, C. krusei, C. lusitaniae, C. kefyr, C. famata, C.
inconspicua, C. dubliniensis, and C. pelliculosa. Thus, the pic-
ture for voriconazole, in terms of spectrum and potency versus
Candida spp., looks quite favorable. Emerging resistance, es-
pecially among C. glabrata, C. tropicalis, and C. rugosa, bears
close monitoring.
Geographic variation in the susceptibilities of C. albicans
and C. glabrata to fluconazole and voriconazole. Table 5
presents the in vitro susceptibility results for fluconazole and
voriconazole tested against the two most common species of
Candida, C. albicans and C. glabrata, stratified by geographic
region and country of origin for the time period 2001 to 2003.
With the exception of those from India, isolates of C. albicans
were highly susceptible to both fluconazole and voriconazole.
The only other countries where the percentages of C. albicans
susceptible to either agent dropped below 94% were Colombia
(fluconazole, 91.2% S, 6.1% R) and Ecuador (fluconazole,
91.6% S, 4.9% R). Overall, there was no meaningful difference
in the fluconazole or voriconazole susceptibility profile for C.
albicans when stratified by specimen type (96.7% to 99.3% S to
fluconazole; 97.9% to 99.3% S to voriconazole) or by hospital
location (95.3 to 99.1% S to fluconazole; 97.2% to 99.4% S to
voriconazole) (data not shown).
Fluconazole and voriconazole susceptibilities of C. glabrata
isolates varied considerably among the various countries and
geographic regions. Susceptibilities to fluconazole were lowest
(50%) in Venezuela (29.2% S), Malaysia (34.0% S), Belgium
(39.7% S), the Czech Republic (44.8% S), and South Africa
(49.6%) and highest (80%) in India and the Middle East
(100% S), Brazil (94.9% S), Greece (93.9% S), Canada
(90.6% S), Portugal (87.1% S), Mexico (86.7% S), Poland
(86.4% S), South Korea (83.7% S), Turkey (82.4% S), and
Italy (81.3% S). Overall rates of resistance to fluconazole
among C. glabrata isolates were 10.6% in the Asia-Pacific re-
gion, 13.2% in Latin America, 16.5% in Europe, and 18.0% in
North America (data not shown). These rates of fluconazole
resistance are considerably higher for each geographic region
than those reported previously for blood and normally sterile-
site infection isolates of C. glabrata (range, 2 to 9% R) tested
by BMD between 1992 and 2000 (20).
In contrast to that seen with C. albicans, the susceptibility of
C. glabrata isolates to fluconazole varied according to specimen
type and hospital location. Isolates from blood and normally
sterile sites were the most susceptible (71% S; 14.8% R) and
genital tract isolates were the least susceptible (53.6% S; 21.2%
R) to fluconazole (data not shown). The highest rates of re-
sistance were seen in isolates of C. glabrata from the surgical
intensive-care unit (21.3%), the obstetrics and gynecology ser-
vice (21.5%), the hematology/oncology service (22.6%), and
the neonatal intensive-care unit (35.0%) (data not shown).
Voriconazole was equally or more active than fluconazole
against C. glabrata isolates from all countries and geographic
regions (Table 5). Susceptibilities to voriconazole were lowest
(70%) in Venezuela (32.7% S), Belgium (53.2% S), Malaysia
(59.5% S), the Czech Republic (65.3% S), and Ecuador (66.7%
S) and highest (90%) in India, Turkey and the Middle East
(100% S), Brazil (96.8% S), Canada (95.7% S), Greece
(95.5%), Thailand (92.5%), and Portugal (90.0%). Overall
rates of resistance to voriconazole among C. glabrata isolates
were 4.1% in the Asia-Pacific region, 5.4% in Latin America,
5.6% in Europe, and 9.0% in North America (data not shown).
Our previous results using BMD MIC testing found resistance
rates of 2.2 to 5.4% among blood and normally sterile-site
isolates of C. glabrata tested in 2001 and 2002 (22). Similar to
that seen with C. albicans, there was little variation in the
susceptibility of C. glabrata to voriconazole when stratified by
specimen type. Isolates from blood and normally sterile sites
were the most susceptible (81%) and genital tract isolates were
the least susceptible (70%) to voriconazole (data not shown).
The rates of resistance to voriconazole ranged from 2.5% (neo-
natal intensive-care unit) to 8.2% (hematology/oncology ser-
vice) across the different hospital locations.
Activities of fluconazole and voriconazole against other op-
portunistic yeasts and yeast-like fungi. Although they com-
prise only 3 to 5% of all of the isolates tested in this study, the
number of noncandidal yeasts tested against fluconazole and
voriconazole exceeds that published in the current literature
(1, 3, 21, 26). Lack of standardized methods for testing most of
these fungi may be considered problematic; however, the vast
majority grew well on the MH-MB agar plates, and the zone
diameters were easily determined. For the purposes of this
study, we utilized the interpretive breakpoints for Candida,
and we recognize that they may be adjusted for noncandidal
yeasts in the future. Nevertheless, the data generated for these
organisms are not dissimilar to those obtained using CLSI
BMD MIC methods (1, 3, 21, 26). Using Cryptococcus neofor-
mans as an example, the susceptibilities of the isolates shown
in Table 6 indicated moderate susceptibility to fluconazole and
a very high level of activity for voriconazole. Very similar
findings for these two agents using BMD MIC methods were
TABLE 4. Trends in in vitro resistance to voriconazole among
Candida spp. as determined by CLSI disk diffusion testing
over a 3-year period: ARTEMIS DISK Surveillance
Program, 2001 to 2003a
Species
Resistanceb
2001 2002 2003
n %R n %R n %R
C. albicans 11,980 0.8 15,086 1.0 20,518 1.0
C. glabrata 2,123 9.8 2,625 8.0 3,971 11.0
C. tropicalis 1,350 4.7 1,820 8.0 2,473 7.0
C. parapsilosis 1,205 1.9 1,627 2.0 2,401 1.0
C. krusei 474 8.0 635 6.0 887 8.0
C. guilliermondii 142 4.2 235 6.0 256 5.0
C. lusitaniae 106 2.8 129 2.0 210 2.0
C. rugosa 129 3.1 149 38.0 116 38.0
C. kefyr 75 1.3 85 1.0 171 0.0
C. famata 39 10.3 110 2.0 89 8.0
C. inconspicua 30 6.7 43 5.0 113 5.0
C. norvegensis 31 0.0 18 0.0 42 2.0
C. dubliniensis 19 0.0 26 0.0 18 0.0
C. lipolytica 13 7.7 14 43.0 25 12.0
C. pelliculosa 14 0.0 12 0.0 12 0.0
Candida spp.c 590 4.2 1,958 3.0 1,616 7.0
All Candida 18,320 2.6 24,572 3.0 32,918 3.5
a Isolates obtained from 115 institutions in 35 countries.
b Zone 13 mm. Voriconazole disk diffusion testing was performed in accor-
dance with CLSI M44-A.
c Candida species not otherwise identified.
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TABLE 5. Geographic variation in the in vitro susceptibilities of C. albicans and C. glabrata to fluconazole and voriconazole
as determined by CLSI disk diffusion testing: ARTEMIS DISK Global Surveillance Program, 2001 to 2003a, b
Region/country Antifungal agent
Susceptibility
C. albicans C. glabrata
n %S %R n %S %R
Asia-Pacific
Australia Fluconazole 207 96.6 2.4 74 58.1 16.2
Voriconazole 207 99.0 1.0 74 77.0 9.5
China Fluconazole 1,071 97.1 1.7 307 74.9 13.4
Voriconazole 1,055 98.7 0.7 307 83.4 8.5
India Fluconazole 60 70.0 23.3 6 100.0 0.0
Voriconazole 60 78.3 20.0 6 100.0 0.0
Malaysia Fluconazole 4,327 99.1 0.3 623 34.0 24.1
Voriconazole 3,602 99.5 0.0 518 59.5 0.8
South Africa Fluconazole 3,324 99.4 0.3 355 49.6 21.1
Voriconazole 3,286 99.9 0.1 333 73.3 3.0
South Korea Fluconazole 1,928 99.5 0.2 49 83.7 12.2
Voriconazole 1,848 99.7 0.3 47 83.0 10.6
Taiwan Fluconazole 1,395 95.8 2.7 352 75.6 12.2
Voriconazole 1,389 98.5 1.0 349 84.0 4.9
Thailand Fluconazole 290 97.6 1.4 93 71.0 5.4
Voriconazole 289 98.6 1.0 93 92.5 2.2
Europe
Belgium Fluconazole 1,761 99.5 0.3 224 39.7 42.0
Voriconazole 1,683 99.7 0.3 216 53.2 18.5
Czech Republic Fluconazole 2,633 99.6 0.2 429 44.8 27.5
Voriconazole 2,402 99.9 0.0 412 65.3 8.7
France Fluconazole 1,149 97.7 1.1 265 77.4 15.1
Voriconazole 936 99.4 0.4 202 85.1 5.9
Germany Fluconazole 1,214 94.2 2.8 634 58.5 15.9
Voriconazole 1,214 98.3 0.8 634 72.6 4.3
Greece Fluconazole 223 96.4 3.1 66 93.9 4.5
Voriconazole 223 97.8 2.2 66 95.5 3.0
Hungary Fluconazole 5,036 98.3 0.7 860 58.4 16.9
Voriconazole 4,889 99.6 0.3 821 74.2 3.9
Italy Fluconazole 2,638 97.5 1.8 582 81.3 9.5
Voriconazole 2,638 99.1 0.5 582 88.5 4.1
Netherlands Fluconazole 1,815 98.8 1.0 190 76.3 8.9
Voriconazole 1,815 99.3 0.6 190 87.9 3.7
Norway Fluconazole 187 98.9 1.1 14 71.4 14.3
Voriconazole 187 100.0 0.0 14 71.4 14.3
Poland Fluconazole 476 99.4 0.2 59 86.4 8.5
Voriconazole 351 99.7 0.3 58 89.7 3.4
Portugal Fluconazole 754 97.2 2.7 70 87.1 4.3
Voriconazole 754 98.1 1.7 70 90.0 1.4
Russia Fluconazole 916 98.8 0.9 64 60.9 20.3
Voriconazole 906 99.1 0.9 64 79.7 6.3
Slovakia Fluconazole 1,362 99.0 0.4 155 78.1 4.5
Voriconazole 1,362 98.6 1.3 155 89.7 1.9
Spain Fluconazole 2,617 98.5 0.9 321 62.3 24.0
Voriconazole 2,614 99.5 0.2 321 75.4 7.2
Switzerland Fluconazole 566 97.9 1.1 144 78.5 9.7
Voriconazole 565 99.5 0.5 144 83.3 4.2
Turkey Fluconazole 519 98.3 1.3 17 82.4 11.8
Voriconazole 475 98.3 1.5 15 100.0 0.0
United Kingdom Fluconazole 4,340 98.8 0.5 868 68.4 14.2
Voriconazole 4,055 99.4 0.4 837 77.9 6.0
Middle East
Israel Fluconazole 12 100.0 0.0 1 100.0 0.0
Voriconazole 12 100.0 0.0 1 100.0 0.0
Saudi Arabia Fluconazole 20 100.0 0.0 2 100.0 0.0
Voriconazole 20 100.0 0.0 2 100.0 0.0
Latin America
Argentina Fluconazole 1,595 97.6 1.4 335 74.0 14.9
Voriconazole 1,458 99.5 0.0 318 84.9 4.4
Continued on following page
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recently reported from our laboratory (26). As noted previ-
ously (21), most of these noncandidal yeasts were substantially
less susceptible to both fluconazole and voriconazole than
Candida species. Although voriconazole was more active than
fluconazole for each of these different genera, it is notable that
less than 80% of Trichosporon beigelii/Trichosporon cutaneum,
Trichosporon asahi, and Rhodotorula spp. were susceptible to
either of these agents. The diverse array of opportunistic yeasts
and yeast-like fungi and their variable susceptibilities to these
azole antifungals emphasize the need for prompt identification
of noncandidal yeasts from clinical material. The flexibility of
the CLSI disk diffusion method may well be an advantage in
assessing the antifungal susceptibilities of these “emerging”
pathogens.
Conversion of zone diameters to MICs. In addition to using
image analysis technology to measure and record the zones of
inhibition surrounding an antifungal disk, the BIOMIC system
uses previously developed scatter plots and regression analysis to
calculate MICs based on the relationship between the zone di-
ameter and the MIC (Fig. 2). The data in Fig. 2 show the corre-
lation between the MIC and the zone diameter for voriconazole
with Candida spp. As seen previously with fluconazole (6, 19, 25),
an excellent correlation was observed. Based on these data, the
voriconazole MICs for Candida spp. were calculated and the data
were compared to BMD MICs published previously (24) for the
same species (Table 7). Although the numbers of isolates tested
are considerably different in the two groups, it is readily apparent
that the MIC50 and MIC90 values are very close for each species,
as is the percent resistant. Thus, the large amount of qualitative
disk diffusion data presented here can be converted to quantita-
tive MIC data for purposes of comparing the activities of flucon-
azole and voriconazole for individual species (Fig. 3) or poten-
tially for following trends across time. Additional work in this area
is warranted.
DISCUSSION
The ARTEMIS Global Antifungal Surveillance Program is
the largest and most comprehensive program of its kind and
the only one to incorporate many of the features that arguably
constitute an “ideal” resistance surveillance program (7–9, 11,
30). It is longitudinal and global, employs standardized meth-
ods used for “routine” testing in participating laboratories and
for “reference” testing in a central reference laboratory, uses
electronic data capture and storage in a central database, and
conducts external validation of the data generated by partici-
pating laboratories. The current report from the ARTEMIS
TABLE 5—Continued
Region/country Antifungal agent
Susceptibility
C. albicans C. glabrata
n %S %R n %S %R
Brazil Fluconazole 1,401 99.6 0.1 410 94.9 3.9
Voriconazole 1,288 99.8 0.0 405 96.8 1.0
Colombia Fluconazole 1,315 91.2 6.1 99 75.8 17.2
Voriconazole 1,263 94.9 4.0 90 80.0 7.8
Ecuador Fluconazole 1,169 91.6 4.9 33 60.6 27.3
Voriconazole 1,093 96.4 0.7 33 66.7 12.1
Mexico Fluconazole 186 98.4 1.1 15 86.7 13.3
Voriconazole 179 98.3 1.7 15 73.3 6.7
Venezuela Fluconazole 550 94.4 2.7 48 29.2 60.4
Voriconazole 525 96.6 2.5 49 32.7 38.8
North America
Canada Fluconazole 297 100.0 0.0 117 90.6 5.1
Voriconazole 297 100.0 0.0 117 95.7 1.7
United States Fluconazole 2,638 94.8 4.4 1,159 75.9 19.3
Voriconazole 2,644 97.0 2.2 1,161 82.1 9.7
a Isolates obtained from 115 institutions in 35 countries.
b Fluconazole and voriconazole disk diffusion testing was performed in accordance with CLSI M44-A. Interpretive breakpoints: S, 19 mm (fluconazole), 17 mm
(voriconazole); R, 14 mm (fluconazole), 13 mm (voriconazole).
TABLE 6. In vitro susceptibilities of non-Candida yeasts to
fluconazole and voriconazole as determined by CLSI disk
diffusion testing: ARTEMIS DISK Surveillance
Program, 2001 to 2003a
Species
Susceptibility
Fluconazoleb Voriconazoleb
n %S %R n %S %R
Cryptococcus neoformans 1,281 79.1 9.8 1,266 97.2 11.7
Cryptococcus spp.c 50 68.0 16.0 50 86.0 10.0
Saccharomyces cerevisiae 413 86.9 6.8 401 94.8 3.2
Trichosporon spp.d 291 80.8 11.3 270 92.9 2.6
T. beigelii/T. cutaneum 80 73.8 15.0 78 79.5 15.4
T. mucoides 14 100.0 0.0 14 100.0 0.0
T. asahii 6 50.0 33.3 6 66.7 33.3
Rhodotorula spp.e 139 30.9 65.5 137 43.1 51.1
Blastoschizomyces capitatus 55 76.4 16.4 55 89.1 5.5
Pichia spp.f 27 81.5 11.1 26 100.0 0.0
Hansenula anomala 13 69.2 7.7 13 92.3 7.7
a Isolates obtained from 115 institutions in 35 countries.
b Fluconazole and voriconazole disk diffusion testing was performed in accor-
dance with CLSI M44-A. Interpretive breakpoints: S, 19 mm (fluconazole),
17 mm (voriconazole); R, 14 mm (fluconazole), 13 mm (voriconazole).
c Cryptococcus species other than C. neoformans.
d Trichosporon species not otherwise identified.
e Rhodotorula species not otherwise identified.
f Pichia species not otherwise identified.
5854 PFALLER ET AL. J. CLIN. MICROBIOL.
 o
n
 July 10, 2014 by CENTRO
 HO
SPITALAR DO
 PO
RTO
http://jcm.asm.org/
D
ow
nloaded from
 
DISK Surveillance Study includes more than 140,000 oppor-
tunistic yeast isolates and is by far the largest and most geo-
graphically diverse study of antifungal susceptibility and resis-
tance to date (5, 15, 16, 20, 28). Important findings regarding
species distribution include a steady decrease in the isolation
of C. albicans and an increase in the isolation of C. tropicalis
and C. parapsilosis. Although they are still rare, it appears that
C. rugosa, C. famata, C. inconspicua, and C. norvegensis may be
“emerging” in recent years. Among the noncandidal yeasts,
Cryptococcus neoformans, Saccharomyces, Trichosporon, and
Rhodotorula species are prominent and may prove to be im-
portant due to their decreased susceptibilities to several anti-
fungal agents (21).
Despite the use of a standard protocol, it is recognized that
any surveillance program based on susceptibility tests per-
formed by the participating laboratories needs to include some
measure of quality assurance, beyond simple QC testing, in
order to provide an independent assessment of laboratory per-
formance and validation of the results generated by the various
laboratories (7, 9, 31). One approach to cross-validation that
has been suggested is to use centralized testing with high-
quality microbiology to confirm the trends in routine data
obtained from participating sentinel sites (7–9, 11, 30). Com-
parison of results obtained for isolates tested in participating
laboratories with results obtained for the same organisms
tested in a central reference laboratory would accomplish this
FIG. 2. Correlation of broth microdilution MICs and disk diffusion zone diameters with Candida (1,670 isolates) and voriconazole. ZD, zone
diameter.
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goal (8, 9). This approach has been used to validate and sup-
port the epidemiologic relevance of findings from antibacterial
surveillance programs (9, 30). Most recently, we have used the
same approach to validate fluconazole and voriconazole disk
test results generated by laboratories participating in the
ARTEMIS Program (25, 27). More than 2,900 isolates of
Candida obtained from blood and normally sterile-site infec-
tions were tested against fluconazole and voriconazole by
ARTEMIS participating laboratories (CLSI disk test) and by
the central reference laboratory (CLSI disk and BMD MIC
tests) (25, 27). Categorical agreement between the reference
MIC results and the disk diffusion test results performed in the
participant laboratories was 87.4% and 94.1% for fluconazole
and voriconazole, respectively (Table 8). A similar level of
agreement was seen when the disk test results obtained in the
reference laboratory were compared with those from the par-
ticipant laboratories (references 25 and 27 and data not
shown). It was noted that participating laboratories tended to
err on the side of calling isolates more resistant than the
reference laboratory did; however, the numbers of major and
very major discrepancies were quite small (Table 8). This ex-
ternal quality assurance data, coupled with excellent QC per-
formance, ensures the generation of accurate and useful sur-
veillance data in the ARTEMIS DISK Surveillance Program.
The data reported here for the more common species of
Candida (i.e., C. albicans, C. glabrata, C. parapsilosis, and C.
tropicalis) confirm most of the previously published data re-
garding their susceptibilities to fluconazole and voriconazole
(5, 16, 20, 24). The activity of fluconazole remains high against
C. albicans, C. parapsilosis, and C. tropicalis, although resis-
tance may be increasing among C. tropicalis isolates. Flucon-
FIG. 3. Cumulative susceptibilities of Candida species to fluconazole and voriconazole using calculated MICs: (A) C. albicans (47,584 isolates
[voriconazole]; 49,991 isolates [fluconazole]); (B) C. glabrata (8,719 isolates [voriconazole]; 9,040 isolates [fluconazole]); (C) C. parapsilosis (5,233
isolates [voriconazole]; 5,539 isolates [fluconazole]); (D) C. tropicalis (5,643 isolates [voriconazole]; 5,959 isolates [fluconazole]).
TABLE 7. Voriconazole MICs for Candida spp. calculated from
disk zone diameter measurements and MIC versus zone diameter
regression plots: comparison with ARTEMIS BMD MIC resultsa
Species
Calculated MIC
(g/ml) and %Rb
ARTEMIS BMD MIC
(g/ml) and %Rb, c
n 50%d 90%d %R n 50%d 90%d %Rb
C. albicans 47,584 0.02 0.09 0.7 2,359 0.007 0.015 1.0
C. glabrata 8,719 0.36 2.08 5.8 607 0.25 1.0 4.0
C. parapsilosis 5,233 0.02 0.16 0.8 439 0.015 0.12 1.0
C. tropicalis 5,643 0.11 0.86 2.4 319 0.06 0.12 1.0
C. krusei 1,996 0.24 0.95 1.7 114 0.25 0.5 0.0
C. lusitaniae 445 0.01 0.12 1.6 42 0.007 0.06 0.0
C. pelliculosa 38 0.09 0.26 0.0 16 0.25 0.5 0.0
a BMD testing was performed as described in CLSI M27-A2, and disk diffusion
testing was performed as described in CLSI M44-A.
b %R, percent resistant to voriconazole (MIC  4 g/ml).
c Data abstracted from Pfaller et al. (24).
d 50% and 90%, MIC encompassing 50% and 90% of isolates tested, respec-
tively.
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azole resistance was considerable among isolates of C. glabrata,
although the extent of resistance varied widely throughout the
world. Fortunately, voriconazole remains quite active against
this species. It is notable, however, that resistance to voricon-
azole has increased among C. glabrata isolates over the 3-year
period of this study and was quite high in certain countries,
such as Belgium (18.5%) and Venezuela (38.8%), where flu-
conazole resistance was also widespread. Again, our previous
studies have shown that compared to reference laboratory test-
ing of C. glabrata by MIC and disk methods, the fluconazole
and voriconazole disk test results reported by ARTEMIS par-
ticipating sites tended to overestimate resistance (25, 27).
Thus, the rates of resistance to fluconazole and voriconazole
reported in this study for C. glabrata may be somewhat higher
than previously reported in the literature. Nevertheless, the
geographical and temporal comparisons and differences re-
main important.
The ARTEMIS database is most valuable as it pertains to
the less common species of Candida (Table 2). The excellent
activity of voriconazole against C. krusei was confirmed by the
results from almost 2,000 clinical isolates. Similarly, the high
levels of activity of both azoles against C. lusitaniae, C. kefyr, C.
dubliniensis, and C. pelliculosa were clearly demonstrated, con-
firming previous results based on comparatively few isolates
(21, 23). Equally important was the demonstration of generally
poor activities of fluconazole against C. guilliermondii, C.
rugosa, C. famata, C. inconspicua, C. norvegensis, C. lipolytica,
and C. zeylanoides. In most instances, these findings confirm
what can only be called preliminary observations (21); how-
ever, for some of these species, these constitute new data and
serve to underscore the imperative to identify Candida to the
species level. Although voriconazole is active against the vast
majority of these rare species, it is notable that decreased
susceptibility to this agent, as well as to fluconazole, is seen
with C. rugosa, C. lipolytica, and C. zeylanoides. These findings
are especially important for C. rugosa, as the frequency of
isolation of this species appears to be increasing over time
(Table 1), it has been shown to cause clusters of nosocomial
infection that are poorly responsive to amphotericin B (2, 4),
and it was previously considered highly susceptible to voricon-
azole based on results for less than 20 clinical isolates (21).
As is the case for the less common Candida species, new
information for noncandidal yeasts is provided by this data set.
Although the antifungal susceptibility profile of Cryptococcus
neoformans is well known (1, 26), much less is known of the
susceptibilities of Saccharomyces, Trichosporon, Rhodotorula,
and Blastoschizomyces species to fluconazole and voriconazole
(3, 21, 33). The results presented in Table 6 indicate that most
of these opportunistic yeasts have decreased susceptibility to
fluconazole, and although voriconazole is clearly more active
than fluconazole, decreased susceptibility to that agent is also
seen with certain species of Trichosporon and with Rhodotorula
spp. The fact that these yeast-like fungi are also nonsuscep-
tible to the echinocandins (they lack -1,3-D-glucan) and
respond variably to amphotericin B highlights the potential
for their emergence as difficult-to-treat mycotic pathogens
in the future (21, 33).
Finally, the ability of the BIOMIC software to convert disk
diffusion zone diameters to MICs is an important feature of the
ARTEMIS surveillance program, providing quantitative data
that will be valuable in trend analysis. We have extended the
previous work of Hazen et al. (6) and have shown that the
voriconazole MICs calculated from the disk diffusion data for
Candida spp. compare very favorably to those obtained by
BMD MIC testing performed centrally (Table 7).
In summary, we present a tremendous volume of data describ-
ing temporal and geographic trends in the isolation and azole
susceptibilities of opportunistic yeast pathogens. The data point
to the strength of azole coverage for most of these organisms but
also highlight several areas where resistance may be progressing
and/or previously rare species may be “emerging.” The strength
of the ARTEMIS Global Surveillance Program is in the overall
design, incorporating standardized test methods, “routine” and
centralized testing of isolates, and a broad international net-
work of study sites providing consistent data over time. The
continued efforts of this surveillance program will provide data
on pathogen frequency and antifungal susceptibility on a global
scale.
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TABLE 8. Interpretive agreement between results of fluconazole
and voriconazole disk diffusion tests and standard 48-h BMDa, b
Antifungal
agent
(no. tested)
Test
methode
% of resultsc %
Agreement f
% Errorsd
S SDD R VME ME M
Fluconazole Ref.-MIC 91.6 6.7 1.7
(2,949) Part.-disk 87.9 4.5 7.6 87.4 0.2 3.3 9.1
Voriconazole Ref.-MIC 99.4 0.2 0.4
(2,934) Part.-disk 94.0 2.1 3.9 94.1 0.1 3.4 2.4
a Fluconazole and voriconazole disk diffusion testing was performed according
to CLSI M44-A, and BMD MIC testing was performed according to CLSI
M27-A2.
b Data compiled from references 25 and 27.
c MIC and disk zone interpretive categories were as follows: fluconazole,
S, MIC  8 g/ml (19 mm), SDD, MIC 16 to 32 g/ml (15 to 18 mm), R,
MIC  64 g/ml (14 mm); voriconazole, S, MIC  1 g/ml (17 mm), SDD,
MIC  2 g/ml (14 to 16 mm), R, MIC  4 g/ml (13 mm).
d % Errors: VME, very major error; ME, major error; M, minor error.
e Ref.-MIC, MIC testing performed by ARTEMIS reference laboratory; Part.-
disk, disk diffusion testing performed by ARTEMIS participants.
f % Agreement, percent categorical agreement between disk diffusion and
MIC test results.
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